{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:52:05Z","timestamp":1790823125638,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012463","name":"Eck Institute for Global Health, University of Notre Dame","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ijantimicag.2019.07.013","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T02:03:46Z","timestamp":1563242626000},"page":"496-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds"],"prefix":"10.1016","volume":"54","author":[{"given":"Hannah N.","family":"Corman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Shoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Norris-Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce J.","family":"Melancon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4115-8464","authenticated-orcid":false,"given":"Mary Ann","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0001","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives","volume":"27","author":"Desjeux","year":"2004","journal-title":"Compar Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0002","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0003","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","article-title":"Leishmaniasis","volume":"354","author":"Herwaldt","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0004","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S2214-109X(13)70078-0","article-title":"The drug and vaccine landscape for neglected diseases (2000\u201311): a systematic assessment","volume":"1","author":"Pedrique","year":"2013","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0005","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/571242","article-title":"Use of antimony in the treatment of leishmaniasis: current status and future directions","volume":"2011","author":"Haldar","year":"2011","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0006","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","article-title":"Leishmaniasis: current status of available drugs and new potential drug targets","volume":"5","author":"Singh","year":"2012","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: a 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0008","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery for infectious diseases of the developing world","volume":"14","author":"Katsuno","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0009","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1021\/acs.jmedchem.5b01456","article-title":"Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity","volume":"58","author":"Mowbray","year":"2015","journal-title":"J Medic Chem"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0166-6851(03)00142-7","article-title":"An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans","volume":"130","author":"Goyard","year":"2003","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0011","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1128\/AAC.02224-13","article-title":"In vitro screening test using leishmania promastigotes stably expressing mCherry protein","volume":"58","author":"Vacchina","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0012","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/expr.2001.4656","article-title":"A lipophosphoglycan-independent method for isolation of infective leishmania metacyclic promastigotes by density gradient centrifugation","volume":"99","author":"Spath","year":"2001","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0013","doi-asserted-by":"crossref","first-page":"e1927","DOI":"10.1371\/journal.pntd.0001927","article-title":"Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis","volume":"6","author":"Calvo-Alvarez","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0014","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomolec Screen"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0015","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource","volume":"5","author":"Pena","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0016","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2015.04.028","article-title":"Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents","volume":"96","author":"Mendoza-Martinez","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0017","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1021\/jm5000408","article-title":"Antileishmanial activity of a series of N(2),N(4)-disubstituted quinazoline-2,4-diamines","volume":"57","author":"Van Horn","year":"2014","journal-title":"J Medic Chem"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0018","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1016\/j.bmc.2015.02.020","article-title":"SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines","volume":"23","author":"Zhu","year":"2015","journal-title":"Bioorg Medic Chem"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0019","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/expr.1997.4207","article-title":"Biochemical and genetic tests for inhibitors of leishmania pteridine pathways","volume":"87","author":"Hardy","year":"1997","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2019.07.013_bib0020","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/AAC.33.11.1860","article-title":"Antileishmanial activities of 2,4-diaminoquinazoline putative dihydrofolate reductase inhibitors","volume":"33","author":"Berman","year":"1989","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:01Z","timestamp":1760376781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0924857919301931"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.07.013","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a target-free high-throughput screening platform for the discovery of antileishmanial compounds","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}